Bliss GVS Pharma Limited has informed the Exchange regarding Change in Auditors of the company.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board, at its May 12, 2025 meeting, approved the audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with the statutory auditor (Kalyaniwalla & Mistry LLP) issuing an unmodified opinion. On a standalone basis, revenue from operations grew about 10% to Rs. 667.2 crore and net profit jumped around 36% to Rs. 68.97 crore, with diluted EPS of Rs. 6.50 versus Rs. 4.77 last year. The board recommended a final dividend of Rs. 0.50 per share (50% on face value of Rs. 1), subject to shareholder approval. M/s. BDO India LLP was re-appointed as Internal Auditor for FY26 and M/s. AVS & Associates was appointed as Secretarial Auditor for five years (FY26-FY30). The company's wholly owned subsidiary will sell its 51% stake in step-down subsidiary Greenlife Bliss Healthcare Ltd (Nigeria) to the existing non-controlling shareholder Greenlife Pharmaceuticals Ltd for USD 13 lakh, with the deal expected by September 30, 2025. Additionally, up to 12.1 lakh sweat equity shares will be issued for non-cash consideration at Rs. 148.72 per share to Managing Director Gagan Harsh Sharma (8.5 lakh shares) and Vice President Vishal Vijay Rao (3.6 lakh shares), pending shareholder approval. The 40th AGM is scheduled for July 31, 2025 via video conferencing.
Positive set of developments: strong FY25 earnings growth, a modest dividend, clean audit opinion and the divestiture of a loss-making step-down subsidiary (which had been impaired last year) should be viewed as value-accretive. The sweat equity issuance will cause some dilution but ties key management to the company. Overall, the board's decisions support the ongoing turnaround narrative and are broadly shareholder-friendly.